Article
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
Oncology reports - 1 Feb 2007
Salgado Josefa, Zabalegui Natalia, Gil Carmen, Monreal Ignacio, Rodríguez Javier, García-Foncillas Jesús
Abstract excerpt
Pharmacogenetics is an increasingly useful field where the genetic studies are becoming an important tool for predicting drug toxicity and/or efficacy. Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) gene polymorphisms could be highly informative tools in the clinical handling of colorectal cancer patients, who are following fluoropyrimidine based chemotherapy. Fifty-eight patients, with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
